Does Ozempic or Mounjaro make you tired? Fatigue in the trials
Reviewed 11 sourcesPublished by PepVault
Tiredness on Ozempic, Wegovy, Mounjaro and Zepbound: each label's trial rate against placebo, when it shows up, the likely causes, and what helps.

- Last reviewed
- Sources
- 11
- Questions
- 6
- Compounds
- 2
The short answer
Sometimes. In the labels' weight trials, 11% of adults on Wegovy 2.4 mg reported tiredness against 5% on placebo, and 5% to 7% on Zepbound against 3%. In the main Ozempic and Mounjaro diabetes trials it missed the labels' 5% lists. In one small trial, a slower dose climb cut weakness by more than half. Fluids, smaller meals, and a climb your prescriber paces help.
Evidence: Tiredness rates come from the four US labels' randomised, placebo-controlled trial pools and two company trials' results records; the timing evidence is a 104-person open-label pilot, and the energy scores are company-funded analyses of trial surveys.

How common is tiredness on Ozempic, Wegovy, Mounjaro and Zepbound?
Common enough to be on two of the four labels' main lists. Ozempic and Wegovy are semaglutide; Mounjaro and Zepbound are tirzepatide. Each label pools its placebo-controlled trials and counts every side effect people reported, whether or not the medicine caused it. Placebo, a dummy shot, shows how often the same complaint turns up anyway. Here is each label's number for tiredness, as of the current US labels (November 2026)1234:
| Brand and dose | Trials in the label | Tiredness | Placebo |
|---|---|---|---|
| Wegovy 2.4 mg | 3 weight trials, up to 68 weeks, 2,116 people on Wegovy | 11% | 5% |
| Wegovy 2.4 mg | 2 weight trials of the 7.2 mg dose, 72 weeks, 304 people on 2.4 mg | 9% | 5% |
| Wegovy 7.2 mg | The same 2 trials, 1,311 people on 7.2 mg | 11% | 5% |
| Zepbound 5 mg | 2 weight trials, up to 72 weeks | 5% | 3% |
| Zepbound 10 mg | The same 2 trials | 6% | 3% |
| Zepbound 15 mg | The same 2 trials | 7% | 3% |
| Ozempic 0.5 or 1 mg | 2 diabetes trials, 33 weeks on average | Not on the 5% list; named among effects over 0.4% | Not given |
| Mounjaro 5, 10 or 15 mg | 2 diabetes trials, 37 weeks on average | Not on the 5% list | Not given |
| Mounjaro, highest dose tolerated | Heart trial in 6,647 people, against dulaglutide | 10% | No placebo group |
The labels count several words as one. Wegovy's row holds fatigue and asthenia, the medical word for weakness; Zepbound's holds asthenia, fatigue, lethargy and malaise, a general unwell feeling12. The labels also warn that rates from different trials cannot be compared directly12.
Read the gap, not the headline. On Wegovy 2.4 mg the medicine adds about 6 points over placebo; on Zepbound it adds 2 to 4, rising with the dose12. Ozempic and Mounjaro give no figure from their main diabetes trials: their tables list only effects in 5% or more that beat placebo, and tiredness is not on them34. In the Wegovy tablet's trial, the kinds and rates of common side effects were similar to the 2.4 mg shot's1.
PepVault's daily check-in records your energy in one tap, and a Fatigue tag, beside the doses you log, so a tired stretch after a dose step is written down by date. Log it in PepVault

Is semaglutide or tirzepatide more tiring?
Close to even when the two meet in one trial. In SURMOUNT-5, 751 adults with obesity or overweight and no diabetes took Zepbound or Wegovy for 72 weeks at the highest dose each person tolerated. Fatigue was reported by 10.4% on tirzepatide and 12.2% on semaglutide, from the trial's results record5. The trial was open-label, so people knew which medicine they took, and it had no placebo group.
Mounjaro's heart trial compared it with dulaglutide (Trulicity), an older GLP-1, in people with type 2 diabetes and heart disease. Its results record lists asthenia, the weakness term on its own, in 5.2% on tirzepatide and 3.2% on dulaglutide 1.5 mg6. The label gives fatigue as 10% for the same trial without saying which words it counts4. The record lists fatigue on its own only as a serious event, in 4 of 6,647 people, so the label's figure most likely groups several terms, as the Wegovy and Zepbound tables do126.
When does GLP-1 tiredness start, and does it pass?
The labels do not say, but the hints point to the dose climb. No label and no trial table we found gives tiredness by week; the labels count it once over the whole trial. What they do time is the stomach side effects: most came while the dose was being stepped up and decreased over time12. Zepbound's label adds that the slowing of the stomach was strongest after the first dose and eased with the doses that followed2.
One trial tested the climb itself. In a 26-week pilot, 104 adults with type 2 diabetes took weekly semaglutide shots on the label's climb (four weeks per step) or on a much slower, flexible one that paused whenever stomach effects came. Weakness was reported by 24.5% on the label's climb and 9.8% on the slow one, and final doses ended up similar7. It was small and open-label, so treat it as a hint that the speed of the climb matters for how tired people feel.
Commonly reported: tiredness or nausea for a day or two after the weekly shot, mostly in the weeks after a dose increase, settling as the dose holds steady.
Do people have less energy after a year on a GLP-1?
On average, slightly more. SURMOUNT-1 asked 2,539 adults the SF-36, a standard health survey whose vitality scale measures energy and tiredness. Scores are set so the US average is 50, and higher is better8. After 72 weeks, vitality rose by 2.3 to 3.2 points on the three Zepbound doses against 0.2 on placebo8.
Semaglutide's trials point the same way. In STEP 1 to 4, the 68-week Wegovy trials, physical functioning improved more than on placebo in STEP 1, 2 and 4, and every other SF-36 scale, vitality included, came out numerically better on semaglutide than placebo, except one emotional scale in STEP 29. Both analyses come from the companies' own trials, with company authors. Early tiredness, then, sits beside a longer trend toward feeling more able.
Why would a GLP-1 make you tired?
No label names one cause. Three things in the labels and trials sit right beside it:
- Eating much less. In a 20-week trial in 72 adults, people on semaglutide 2.4 mg ate 35% less at an all-you-can-eat lunch than people on placebo10. That is the medicine working, and it also means less fuel on a day you barely eat.
- Losing fluid. Vomiting and diarrhea can drain fluid, and the Wegovy and Zepbound guides for patients tell you to drink fluids to lower the chance of dehydration12. Low blood pressure was also more common on the medicines, sometimes alongside stomach effects and fluid loss12.
- Low blood sugar, mainly with other diabetes medicines. With a sulfonylurea, 17.3% to 24.4% of people on Ozempic had symptomatic low blood sugar3; on Zepbound, a reading under 54 mg/dL turned up in 10.3% of people with diabetes taking a sulfonylurea, against 2.1% without one2. In adults without diabetes on Zepbound, a reading under 54 mg/dL turned up in 0.3%2. The labels list weakness, drowsiness, shakiness and sweating among its signs12.
PepVault's food log sets one daily target, protein first, so a day when appetite barely lets you eat shows up on the plate instead of only in how you feel. Track your food in PepVault
What helps with tiredness on Ozempic or Mounjaro?
Most of it is in the labels' own advice, and the decisions about doses are your prescriber's:
- Drink fluids through the day, and more on any day with vomiting or diarrhea12.
- On an unsettled day, split your meals into four or more smaller ones and stop when you feel full, as the Zepbound trials advised11.
- If you also use insulin or a sulfonylurea, ask your prescriber how to spot and manage low blood sugar, and about those doses: the labels tell prescribers to consider lowering them when the GLP-1 starts23.
- Note your energy and your doses for a few weeks, so the pattern is plain when you talk to your prescriber.
- Ask about the climb. Wegovy's label lets a prescriber delay a step that is not tolerated, and Zepbound's allows a lower maintenance dose12.
Tiredness that does not fit the climb, or that keeps growing after the dose holds steady, is worth a check of its own: the labels ask you to tell your provider about any side effect that bothers you or does not go away12.
When to get help Tiredness with shakiness, sweating or confusion, especially on insulin or a sulfonylurea, or with vomiting or diarrhea that keeps you from holding fluids down, is a reason to contact your prescriber the same day12.
Sources
- WEGOVY (semaglutide) injection and tablets, US prescribing information and Medication Guide. Novo Nordisk. DailyMed, version 19, June 2026. dailymed.nlm.nih.gov
- ZEPBOUND (tirzepatide) injection, US prescribing information and Medication Guide. Eli Lilly. DailyMed, version 40, August 2026. dailymed.nlm.nih.gov
- OZEMPIC (semaglutide) injection, US prescribing information. Novo Nordisk. DailyMed, version 20, June 2026. dailymed.nlm.nih.gov
- MOUNJARO (tirzepatide) injection, US prescribing information. Eli Lilly. DailyMed, version 40, August 2026. dailymed.nlm.nih.gov
- SURMOUNT-5: tirzepatide vs semaglutide in obesity (NCT05822830). Results, adverse events. ClinicalTrials.gov. Sponsor: Eli Lilly. clinicaltrials.gov
- SURPASS-CVOT: tirzepatide vs dulaglutide on cardiovascular events in type 2 diabetes (NCT04255433). Results, adverse events. ClinicalTrials.gov. Sponsor: Eli Lilly. clinicaltrials.gov
- Eldor R et al. Gradual titration of semaglutide results in better treatment adherence and fewer adverse events: a randomized controlled open-label pilot study. Diabetes Care. 2025;48(9):1607-1611. PubMed 40673973
- Gudzune KA et al. Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: results from the SURMOUNT-1 study. Diabetes Obes Metab. 2025;27(2):539-550. PubMed 39497468
- Rubino D et al. Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: patient-reported outcomes from the STEP 1-4 trials. Diabetes Obes Metab. 2024;26(7):2945-2955. PubMed 38698650
- Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-762. PubMed 33269530
- Rubino DM et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes Obes Metab. 2025;27(4):1826-1835. PubMed 39789843
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.